title: [Hemorrheology and quality of life in fibrinogen- and lipid-lowering therapy].
abstract: Previous studies have demonstrated that heparin-induced extracorporeal LDL precipitation is able to reduce total cholesterol, LDL, triglycerides and plasma fibrinogen at the same time and thus improve the hemorheologic pattern. A combination of H.E.L.P. and bezafibrate, which also has a lipid- and fibrinogen-lowering potency, was applied in patients suffering from cerebral multi-infarct dementia and disturbances of the hemorheologic situation. In view of observations regarding improved quality of life after H.E.L.P., a prospective, randomized trial was conducted to determine possible interactions between improved hemorheology and better quality of life. To obtain a low baseline of laboratory parameters, all the patients underwent a single H.E.L.P. session and were then (double-blind) stratified into 2 groups: group 1 (16 males, 5 females, age 67.9 +/- 6.8 years) received sustained-release bezafibrate 400 mg (Bezalip) per day, while group 2 served as controls, and comprised 14 males and 5 females (age 69.2 +/- 6.8 years) who received placebo for a period of 56 days. After H.E.L.P. a statistically significant reduction of the following parameters relevant to hemorheology was obtained: fibrinogen (p < 0.0001), whole blood viscosity (low shear rate p < 0.007 and high shear rate p < 0.005), plasma viscosity (p < 0.002) and red cell transit time (p < 0.0001). Also, the metabolic parameters were influenced positively (p < 0.0001 for total cholesterol, LDL and triglycerides).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Universitäts-Klinik für Neurologie Graz.
authors.forename: M
authors.initials: M
authors.lastname: Walzl
authors.forename: H
authors.initials: H
authors.lastname: Lechner
authors.forename: B
authors.initials: B
authors.lastname: Walzl
authors.forename: G
authors.initials: G
authors.lastname: Kleinert
authors.forename: G
authors.initials: G
authors.lastname: Schied
authors.forename: W
authors.initials: W
authors.lastname: Freidl
authors.forename: G
authors.initials: G
authors.lastname: Bertha
mesh_terms: D000368:Aged; D001629:Bezafibrate / Q000008:administration & dosage / Q000627:therapeutic use*; D001809:Blood Viscosity; D008078:Cholesterol, LDL / Q000097:blood; D015161:Dementia, Multi-Infarct / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D006440:Hemofiltration / Q000379:methods; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008055:Lipids / Q000097:blood; D008297:Male; D008609:Mental Status Schedule; D011788:Quality of Life
chemical_list: D008078:Cholesterol, LDL; D008055:Lipids; D005340:Fibrinogen; D006493:Heparin; D001629:Bezafibrate
vernacular_title: Hämorheologie und Lebensqualität bei Fibrinogen- und Lipid-senkender Therapie.